Jarrett McGehee, MD
Interventional Cardiology · San Antonio, TXNPI 1396774063
Payments from drug & device makers
Across 475 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Abiomed$941
- Johnson & Johnson$784
- Alnylam Pharmaceuticals Inc.$725
- Pfizer$622
- Merck$518
- plus $4K from 28 others
What the payments were for
- Food & beverage$8,99099%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 80 | $1,143 |
| Abiomed | 9 | $941 |
| Johnson & Johnson | 40 | $784 |
| Alnylam Pharmaceuticals Inc. | 31 | $725 |
| Pfizer | 53 | $622 |
| Merck | 32 | $518 |
| Amgen | 25 | $465 |
| Esperion Therapeutics, Inc. | 32 | $440 |
| Amarin Pharma, Inc. | 27 | $428 |
| Boehringer Ingelheim | 20 | $391 |
| Celonova Biosciences, Inc. | 2 | $387 |
| AstraZeneca | 19 | $298 |
| Boston Scientific | 16 | $279 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $258 |
| Sanofi-aventis U.S. LLC | 13 | $216 |
| Arbor Pharmaceuticals, Inc. | 11 | $168 |
| Shockwave Medical, Inc | 2 | $149 |
| Bayer | 6 | $142 |
| Scpharmaceuticals Inc. | 5 | $113 |
| Irhythm Technologies, Inc. | 5 | $107 |
| E.r. Squibb & Sons, L.L.C. | 5 | $75 |
| GSK | 3 | $60 |
| Azurity Pharmaceuticals, Inc. | 4 | $58 |
| Lundbeck LLC | 3 | $55 |
| Impulse Dynamics (USA) Inc. | 2 | $54 |
| Lexicon Pharmaceuticals, Inc. | 3 | $47 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| AbbVie | 1 | $25 |
| Medicomp Inc | 1 | $21 |
| Althera Pharmaceuticals LLC | 1 | $18 |
| Agepha Pharma FZ LLC | 1 | $16 |
| Avinger Inc. | 1 | $14 |
| Preventice Services, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$767
- Vascular Lithotripsy$123
How this compares
$9,089 in reported general payments places this provider in the 45th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 193 | $193,335 |
| XareltoRivaroxaban | 77 | $82,295 |
| Repatha SureclickEvolocumab | 63 | $54,856 |
| EntrestoSacubitril/Valsartan | 38 | $43,132 |
| JardianceEmpagliflozin | 21 | $20,490 |
| FarxigaDapagliflozin Propanediol | 24 | $17,845 |
| Praluent PenAlirocumab | 16 | $11,792 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $10,202 |
| Droxidopa | 17 | $9,500 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,504 |
| NexletolBempedoic Acid | 12 | $5,870 |
| Ranolazine ErRanolazine | 57 | $5,588 |
| Metoprolol Succinate | 229 | $2,885 |
| Rosuvastatin Calcium | 164 | $2,175 |
| Nebivolol Hcl | 23 | $1,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $622 | $193,335193 claims |
| Johnson & JohnsonXarelto | $784 | $82,29577 claims |
| NovartisEntresto | $1,143 | $43,13238 claims |
| Boehringer IngelheimJardiance | $391 | $20,49021 claims |
| AstraZenecaFarxiga | $298 | $17,84524 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $440 | $16,07223 claims |
| GSKTrelegy Ellipta | $60 | $7,50412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in San Antonio
- Jorge AlvarezSan Antonio$1.6M
- Robert ChiltonSan Antonio$1.3M
- Marvin EngSan Antonio$756K
- Nandish ThukralSan Antonio$368K
- Anand PrasadSan Antonio$328K
- Jose PerezSan Antonio$312K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.